Pacira Pharma (PCRX) Tops Q4 EPS by 12c ; Offers Guidance

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.91, $0.12 better than the analyst estimate of $0.79. Revenue for the quarter came in at $187.3 million versus the consensus estimate of $180.22 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-765 million, versus the consensus of $747.6 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Microsoft (MSFT) Reiterated at Market Outperform by Citizens as Cowork Rollout Announced
• Keurig Dr Pepper coffee chief to depart ahead of planned split